OakChart

Elutia Inc

ELUTHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 11:35 AM ET

0.9202-0.0127 (-1.36%)
2026-11-11 17:50 CET
Market cap
41.32 USD m
Revenue, TTM
9.95 USD m
Net income, TTM
-22.31 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.51
P/E
-
Compare

Price

ELUT against its 20, 50 and 200-day averages
2050200missearnings
0.801.001.203.0M6.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ELUTclose 0.9220-day 0.8250-day 0.82200-day 0.970.92

33.6% under the 52-week high of 1.39 on 4 Mar 2026. 52-week low 0.50 on 17 Dec 2025. Last 15 sessions, 36.4% high to low

Profile

ELUT
52-week range, 48% of the way up
0.501.38

Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women's Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Gaithersburg, MD.

Employees26
IPOOct 08, 2020
Beta0.90
ATR, 14d0.07
Rel volume0.31
Short float0.10%
Insider own20.15%
Inst own26.54%

Snapshot

6 groups

Valuation

Index-
Market Cap40.76M
Enterprise Value25.37M
Income-22.31M
Sales9.95M
Book/sh0.36
Cash/sh0.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees26
IPOOct 08, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S4.10
P/B2.59
P/C1.40
P/FCF-
EV/EBITDA-
EV/Sales2.55
Quick Ratio2.61
Current Ratio2.63
Debt/Eq0.89
LT Debt/Eq0.53
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.51
EPS next Y-0.63
EPS next Q-0.16
EPS this Y-175.86%
EPS next Y4.55%
EPS next 5Y-
EPS past 3/5Y30.73% 20.42%
Sales past 3/5Y-19.82% -22.04%
EPS Y/Y TTM24.77%
Sales Y/Y TTM-52.81%
EPS Q/Q84.81%
Sales Q/Q-65.78%
EarningsNov 05 AMC
EPS/Sales Surpr.73.33% 13.70%

Ownership

Insider Own20.15%
Insider Trans0.00%
Inst Own26.54%
Inst Trans-0.10%
ROA-73.59%
ROE-
ROIC-95.24%
Gross Margin69.29%
Oper. Margin-240.35%
Profit Margin-224.21%
SMA2011.57%
SMA5012.63%
SMA200-5.23%
Trades-

Technical

Shs Outstand44.40M
Shs Float35.36M
Short Float0.10%
Short Ratio0.18
Short Interest0.03M
52W High1.38 -33.56%
52W Low0.50 84.04%
Volatility12.59% 9.75%
ATR (14)0.07
RSI (14)61.77
Beta0.90
Rel Volume0.31
Avg Volume183.57K
Volume22,420

Performance

Perf Week21.14%
Perf Month19.01%
Perf Quarter6.96%
Perf Half Y-12.36%
Perf YTD32.84%
Perf Year11.70%
Perf 3Y-37.40%
Perf 5Y-84.27%
Perf 10Y-
Recom1.00
Target Price5.00
Prev Close0.93
Price0.92
Change %-1.36%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Nov 02, 2020InitiatedTTruistBuy$20+2,073.4%
Nov 02, 2020InitiatedPPiper SandlerOverweight$20+2,073.4%
Nov 02, 2020InitiatedCCowenOutperform$20+2,073.4%
Nov 02, 2020InitiatedCCantor FitzgeraldOverweight$20+2,073.4%

Peers

Mkt cap
TickerCompanyMkt cap
TELATELA Bio Inc37.09M
IARTIntegra Lifesciences Holdings Corp1.13B
AXGNAxogen Inc3.14B
ESTAEstablishment Labs Holdings Inc2.11B
RCELAVITA Medical Inc432.15M
ORGOOrganogenesis Holdings Inc126.01M
LMATLemaitre Vascular Inc1.82B
MDXGMimedx Group Inc490.31M
ANIKAnika Therapeutics Inc186.46M
CRMDCorMedix Inc414.68M

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RAKIN KEVINDirectorJan 30 '26Buy1.0670,00074,200196,120Feb 02 05:01 PM
NEELS GUIDO JDirectorJan 30 '26Buy1.0420,00020,800118,750Feb 02 08:43 AM
NEELS GUIDO JDirectorJan 29 '26Buy1.0615,00015,90098,750Jan 29 05:51 PM
NEELS GUIDO JDirectorJan 28 '26Buy1.0615,00015,90083,750Jan 29 05:51 PM
William Matthew ZugaFormer DirectorDec 23 '25Proposed Sale0.5512,6136,937Dec 23 02:59 PM
RAKIN KEVINDirectorDec 17 '25Buy0.5250,00025,995322,419Dec 19 04:59 PM
Colpman DavidDirectorDec 17 '25Buy0.5112,5006,37531,098Dec 18 09:00 AM
Makes BrigidDirectorDec 17 '25Buy0.5225,00013,00027,000Dec 18 09:00 AM
Mills C RandalPRESIDENT AND CEODec 17 '25Buy0.513,0001,530379,204Dec 18 09:00 AM
Ferguson MatthewCHIEF FINANCIAL OFFICERDec 17 '25Buy0.5360,00031,800447,110Dec 18 09:00 AM
Ferguson MatthewCHIEF FINANCIAL OFFICERDec 02 '25Buy0.675,5003,685379,071Dec 03 08:45 AM
Ferguson MatthewCHIEF FINANCIAL OFFICERDec 01 '25Buy0.654,5002,925373,571Dec 03 08:45 AM
Mills C RandalPRESIDENT AND CEONov 24 '25Buy0.605,0003,000358,785Nov 26 05:00 PM
Colpman DavidDirectorNov 17 '25Buy0.7415,50011,47018,598Nov 19 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 204
  • Elutia's Loss Deepens As NXT-41x R&D Ramps, But Q3 Was About De-Risking: GLP Study Win, $26 Million Non-Dilutive Funding, And A Q4 FDA Filing (Earnings Whispers) +11.52%
  • Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch (GlobeNewswire)
  • Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 (GlobeNewswire)
  • Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 (GlobeNewswire)
  • Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th (GlobeNewswire)
  • Loading…
  • Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch (GlobeNewswire) -6.75%
  • Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... (GuruFocus.com) +9.38%
  • Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results (GlobeNewswire) +5.17%
  • Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market (GlobeNewswire)
  • Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside (GuruFocus.com)
  • Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 (GlobeNewswire) -5.33%
  • Elutia Signs Definitive Agreement to Sell SimpliDerm in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.040-0.150-0.1501.141.001
2026Q22026-08-13-0.170-0.150-0.1732.432.901
2026Q12026-05-14-0.170-0.150-0.1843.113.001
2025Q42026-03-111.480-0.140-0.1283.273.301
2025Q32025-11-06-0.190-0.155-0.1913.326.652
2025Q22025-08-14-0.260-0.170-0.2566.266.552
2025Q12025-05-08-0.210-0.205-0.2136.036.652
2024Q42025-03-06-0.260-0.250-0.2605.475.902
2024Q32024-11-14-0.688-0.440-0.3315.926.602
2024Q22024-08-07-1.140-0.330-1.1326.296.652
2024Q12024-05-09-0.750-0.415-0.7536.696.102
2023Q42024-03-07-0.660-0.285-0.6605.886.552
2023Q32023-11-13-0.500-0.545-0.5736.137.302
2023Q22023-08-14-0.650-0.290-0.65510.3012.501
2023Q12023-05-10-0.490-0.540-0.49413.0513.701
2022Q42023-03-22-0.380-0.690-0.37612.6712.552

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.697-2.845-2.47842.6841.84
2021FY-2.380-2.130-2.37847.3947.61
2022FY-2.380-2.655-2.37849.1949.05
2023FY-2.270-1.890-2.40424.7536.05
2024FY-1.860-1.830-1.85624.3824.80
2025FY0.870-0.480-0.38012.2918.90
2026FY--0.630--7.50
2027FY--0.540--4.30

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-061001.001.001.00
2026Q4S2026-10-281001.001.001.00
2026Q4S2026-08-141011.001.001.00
2026Q4S2026-05-261003.003.003.00
2026Q4S2026-05-151013.003.003.00
2026Q4S2026-03-121013.003.003.00
2026Q4S2026-03-021003.503.503.50
2026Q4S2026-01-212004.353.505.20
2026Q4S2025-11-112104.353.505.20
2026Q4S2025-11-102104.353.505.20
2026Q4S2025-11-092104.353.505.20
2026Q4S2025-11-082104.353.505.20
2026Q4S2025-11-072104.353.505.20
2026Q4S2025-11-061014.304.304.30

Estimate history

EPS, annual-1.084-1.119-2.478-2.378-2.378-2.404-1.856-0.791-0.5138
Period20182019202020212022202320242025TTM
EPS, quarterly-0.331-0.26-0.213-0.256-0.191-0.128-0.184-0.173-0.029
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual39.03842.90142.68247.3923.84924.74514.46712.2939.95
Period20182019202020212022202320242025TTM
Sales, quarterly5.9225.4686.036.2633.3233.2713.1142.4271.137
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.66710.66710.22613.55916.13723.19835.21142.78544.289
Period20182019202020212022202320242025MRQ
Shares, quarterly34.56235.21140.86642.39542.5542.78544.20844.289-
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue9.9512.2914.4724.7523.8547.3942.6842.9039.04
Cost of Goods Sold Incl. D&A4.085.707.7513.6912.2128.3722.1223.1323.09
Gross Profit6.896.606.7111.0511.6419.0220.5619.7715.95
Selling, General and Administrative Excl. Other29.7825.0126.0631.5941.6342.0534.1628.1824.17
Research and Development8.694.163.004.407.739.274.082.402.48
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-23.91-18.41-19.34-20.54-29.99-23.03-13.60-8.41-8.22
Interest Expense--0.935.805.125.325.635.385.52
Unusual Expense5.66-3.6426.2514.195.600.000.000.000.00
Net Income Before Taxes-28.48-15.86-45.34-41.22-36.15-24.78-21.80-11.91-11.54
Income Taxes0.070.010.010.030.030.060.030.030.03
Consolidated Net Income-28.55-15.87-45.34-41.25-36.18-24.83-21.82-11.94-11.57
Net Income From Continuing Operations-28.55-15.87-45.34-41.25-36.18-24.83-21.82-11.94-11.57
Net Income-22.31-22.89-53.95-43.66-32.90-24.83-25.34-11.94-11.57
EPS (Recurring)-0.41-0.85-1.22-1.86-2.09-2.38-2.48-1.12-1.08
EPS (Basic, Before Extraordinaries)-0.51-0.55-1.86-2.40-2.38-2.38-2.48-1.12-1.08
EPS (Diluted)-0.51-0.79-1.86-2.40-2.38-2.38-2.48-1.12-1.08
EBITDA--17.20-18.26-17.03-26.42-19.30-9.73-4.51-4.42
Non-Operating Income (Expense)0.88-1.081.19-0.704.563.58-2.571.882.20
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.883.475.561.902.772.580.570.160.19
Price To Sales Ratio3.522.597.521.592.471.393.27--
Gross Margin69.2953.6646.4244.6748.8040.1448.1746.0840.84
Operating Margin-240.35-149.78-133.71-82.99-125.75-48.60-31.86-19.60-21.06
Net Margin-224.21-186.23-372.91-176.42-137.94-52.40-59.36-27.83-29.63
Shares Outstanding-42.7835.2123.2016.1413.5610.2310.6710.67
Market Capitalization41.3241.32129.2650.1168.5385.42139.38130.89-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.142.433.113.273.326.266.035.47
Cost of Goods Sold Incl. D&A0.430.981.311.361.473.213.573.14
Gross Profit0.701.451.801.911.853.062.462.32
Selling, General and Administrative Excl. Other7.487.357.547.416.218.937.818.14
Research and Development2.982.531.971.221.091.460.910.83
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-6.78-5.90-5.74-5.49-4.36-5.87-5.35-5.82
Interest Expense0.28---0.270.521.081.07
Unusual Expense0.121.832.261.45-4.251.77-2.622.17
Net Income Before Taxes-6.50-7.64-7.82-6.52-0.38-9.60-3.92-9.06
Income Taxes0.010.010.07-0.010.010.010.010.00
Consolidated Net Income-6.50-7.65-7.89-6.51-0.38-9.61-3.93-9.06
Net Income From Continuing Operations-6.50-7.65-7.89-6.51-0.38-9.61-3.93-9.06
Net Income-1.28-7.65-7.89-5.48-3.87-9.61-3.93-9.06
EPS (Recurring)-0.03-0.14-0.15-0.10-0.25-0.23-0.26-0.22
EPS (Basic, Before Extraordinaries)-0.03-0.17-0.18-0.13-0.09-0.23-0.10-0.26
EPS (Diluted)-0.03-0.17-0.18-0.13-0.19-0.26-0.21-0.26
EBITDA-6.43-5.55-5.41-6.76-3.63-4.98-4.48-4.96
Non-Operating Income (Expense)0.680.090.180.420.00-1.44-0.100.00
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.680.710.740.751.050.910.960.95
Price To Sales Ratio3.523.572.831.571.983.874.585.35
Gross Margin61.7459.6257.8758.5155.7648.8340.7542.50
Operating Margin-596.22-243.10-184.39-167.87-131.06-93.74-88.72-106.46
Net Margin-113.02-315.04-253.50-167.59-116.40-153.44-65.22-165.71
Shares Outstanding-44.2944.2142.7842.5542.4040.8735.21
Market Capitalization41.3243.3144.9229.5837.7481.41103.39129.26

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments36.3513.2419.2816.9930.4339.532.592.41
Short Term Receivables14.587.045.9617.596.007.177.237.20
Inventories2.621.933.854.249.5510.127.197.46
Other Current Assets2.273.972.1711.881.452.891.441.06
Total Current Assets55.8226.1731.2550.7047.4359.7118.4518.14
Net Property, Plant & Equipment5.000.850.500.561.201.160.990.87
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets1.532.6011.6715.0718.4721.8625.2628.66
Other Assets0.006.500.002.510.080.080.080.08
Total Assets62.3536.1343.4368.8467.1782.8144.7747.74
Short Term Debt Incl. Current Port. of LT Debt4.755.7915.349.2218.0417.8711.156.46
Accounts Payable4.794.152.291.371.582.052.491.59
Other Current Liabilities15.5927.8525.4132.026.386.864.635.29
Total Current Liabilities25.1437.8043.0442.6226.0026.7818.2713.35
Long Term Debt6.4228.1125.7230.1826.9534.4480.6675.92
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities3.1216.4813.281.080.700.760.951.88
Total Liabilities34.6882.3982.0373.8753.6561.9899.8891.15
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity27.67-46.26-38.60-5.0313.5220.83-55.11-43.41
Total Shareholders Equity27.67-46.26-38.60-5.0313.5220.83-55.11-43.41
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity27.67-46.26-38.60-5.0313.5220.83-55.11-43.41
Total Liabilities & Stockholders Equity62.3536.1343.4368.8467.1782.8144.7747.74
Book Value Per Share0.65-1.31-1.66-0.311.002.04-5.17-4.07
Tangible Book Value Per Share0.61-1.39-2.17-1.25-0.36-0.10-7.53-6.76
Full-Time Employees265154164176163--
Price to Book Ratio2.62-3.21-1.18-5.486.326.69-1.82-
Return on Assets-32.23-114.00-73.48-53.20-33.11-34.21-25.81-
Return on Equity----852.54-144.57---
Return on Invested Capital-67.16---130.84-61.36-39.48-46.74-35.57
Quick Ratio2.120.640.641.091.461.850.620.80
Current Ratio2.220.690.731.191.822.231.011.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-53.38-53.95-37.66-32.90-24.83-21.82-11.94-11.57
Depreciation-1.221.083.513.573.733.863.863.82
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)--80.6727.275.431.723.287.001.321.24
Funds from Operations--26.08-25.60-28.72-27.61-17.82-10.96-6.76-6.50
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--18.732.946.965.712.20-2.48-1.691.38
Cash from Operating Activities--44.81-22.66-21.76-21.90-15.62-13.44-8.45-5.12
Capital Expenditures--1.88-0.65-0.35-0.54-0.37-0.64-0.58-0.19
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-80.440.1814.550.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.000.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities-78.56-0.4714.21-0.54-0.37-0.64-0.58-0.19
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Change in Capital Stock-13.9128.2810.3010.4813.9943.430.020.44
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-13.9128.2810.3010.4813.9943.430.020.44
Proceedsfrom Stock Options-0.000.0010.3010.4113.7543.430.000.00
Issuance or Reduction of Debt, Net--23.06-9.40-1.96-0.45-7.104.146.07-3.96
Change in Long Term Debt--23.06-9.40-1.96-0.45-7.284.344.85-3.64
Issuance of Long Term Debt-0.000.000.006.380.007.286.843.00
Reduction of Long Term Debt--23.06-9.40-1.96-6.84-7.28-2.94-1.99-6.64
Net Financing Active Other Cash Flow--1.48-1.781.49-1.030.003.443.1210.51
Other Financing Activities Uses--1.48-3.18-0.50-1.030.000.00-0.04-0.05
Cash from Financing Activities--10.6417.099.849.006.8851.029.206.99
Net Change in Cash-23.11-6.042.29-13.44-9.1036.940.181.67
Free Cash Flow--46.69-23.31-22.11-22.44-15.99-14.07-9.02-5.32

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments29.0919.9028.4936.354.728.50
Short Term Receivables3.995.297.4214.588.117.45
Inventories0.272.652.662.622.015.24
Other Current Assets8.819.3810.032.273.531.09
Total Current Assets42.1737.2248.5955.8218.3822.28
Net Property, Plant & Equipment2.835.445.365.004.624.99
Total Investments and Advances-0.000.000.000.000.00
Intangible Assets0.720.991.261.531.806.58
Other Assets2.480.000.000.004.610.00
Total Assets48.1943.6555.2162.3529.4133.85
Short Term Debt Incl. Current Port. of LT Debt5.607.106.024.7510.728.55
Accounts Payable6.963.533.874.796.606.07
Other Current Liabilities3.4610.4213.8315.5924.0123.32
Total Current Liabilities16.0321.0523.7325.1441.3337.95
Long Term Debt8.103.695.576.4227.8328.78
Provision for Risks Charges4.200.000.000.000.000.00
Other Liabilities4.543.163.393.124.168.97
Total Liabilities32.8727.9032.6834.6873.3375.69
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity15.3215.7522.5327.67-43.92-41.84
Total Shareholders Equity15.3215.7522.5327.67-43.92-41.84
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity15.3215.7522.5327.67-43.92-41.84
Total Liabilities & Stockholders Equity48.1943.6555.2162.3529.4133.85
Book Value Per Share-0.360.510.65-1.03-0.99
Tangible Book Value Per Share-0.330.480.61-1.07-1.14
Full-Time Employees---26--
Price to Book Ratio2.621.921.62-0.67-0.90-2.22
Return on Assets-73.59-57.89-51.63-41.50-59.08-56.86
Return on Invested Capital-5.49-39.33-28.10-16.08--
Quick Ratio2.611.641.942.120.400.45
Current Ratio2.631.772.052.220.440.59

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--7.65-7.4770.79-3.87-9.61
Depreciation-0.350.33-1.270.730.89
Other Funds (Non Cash)-0.132.31-76.55-1.820.91
Funds from Operations--7.17-4.83-7.03-4.96-7.80
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital--1.29-3.00-17.782.07-0.42
Cash from Operating Activities--8.46-7.83-24.81-2.89-8.23
Capital Expenditures--0.09-0.46-0.85-0.63-0.11
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.4280.440.000.00
Purchase or Sale of Investments-0.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--0.09-0.0379.58-0.63-0.11
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-0.000.05-0.000.030.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-0.000.05-0.000.030.00
Proceedsfrom Stock Options-0.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.000.00-23.060.000.00
Change in Long Term Debt-0.000.00-23.060.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.00-23.060.000.00
Net Financing Active Other Cash Flow--0.04-0.04-0.07-0.29-0.52
Other Financing Activities Uses--0.04-0.04-0.07-0.29-0.52
Cash from Financing Activities--0.040.00-23.14-0.26-0.52
Net Change in Cash--8.59-7.8631.63-3.78-8.86
Free Cash Flow--8.55-8.29-25.67-3.52-8.34

Revenue breakdown

Cardiovascular2024: 2.91M 2025: 3.16M
Women's Health2024: 11.55M 2025: 9.14M
United States2024: 14.47M 2025: 12.29M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.10%0.0M35.4M178.59K
2026-10-150.04%0.0M35.4M189.71K
2026-09-300.03%0.0M35.4M61.30K
2026-09-150.02%0.0M35.4M70.48K
2026-08-310.05%0.0M35.4M84.46K
2026-08-140.07%0.0M35.4M89.47K
2026-07-310.11%0.0M35.3M115.14K
2026-07-150.12%0.0M35.3M100.02K
2026-06-300.15%0.1M35.3M104.86K
2026-06-150.07%0.0M35.3M112.37K
2026-05-290.12%0.0M35.4M126.90K
2026-05-150.37%0.1M38.0M140.22K
2026-04-300.36%0.1M34.7M132.92K
2026-04-150.37%0.1M33.6M187.10K
2026-03-310.39%0.1M33.1M239.68K
2026-03-130.32%0.1M31.2M367.49K
2026-02-270.47%0.1M31.2M370.37K
2026-02-130.43%0.1M31.2M373.37K
2026-01-300.52%0.2M31.3M392.72K
2026-01-150.54%0.2M31.5M365.59K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-08-218-KCurrent report2026-08-17SEC
2026-08-14S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-11SCHEDULE 13GSEC
2026-08-078-KCurrent report2026-08-06SEC
2026-07-208-KCurrent report2026-07-16SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-21SEC
2026-06-168-KCurrent report2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-12-10SEC
2026-03-25S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01126.80K400
2025-1285.31K700
2025-1124.58K300

Institutional holders

Manager% owned
Nantahala Capital Management, LLC14.41%
Knollwood Investment Advisory, LLC5.78%
AIGH Capital Management LLC5.72%
SILVERARC CAPITAL MANAGEMENT, LLC4.96%
VANGUARD CAPITAL MANAGEMENT LLC2.58%
PERKINS CAPITAL MANAGEMENT INC1.54%
GEODE CAPITAL MANAGEMENT, LLC0.64%
Corient Private Wealth LP0.57%
RENAISSANCE TECHNOLOGIES LLC0.46%
VANGUARD FIDUCIARY TRUST CO0.39%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.04%
VANGUARD EXTENDED MARKET INDEX FUND0.54%
Fidelity Extended Market Index Fund0.31%
iShares Micro-Cap ETF0.26%
Fidelity Total Market Index Fund0.10%
Fidelity Series Total Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.02%

OakChart. ELUT. Cached 15 minutes.